The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1072
February 21, 2000
View Complete Issue         Table of Contents 2019 
Gatifloxacin and Moxifloxacin: Two New Fluoroquinolones
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Gatifloxacin and Moxifloxacin: Two New Fluoroquinolones
February 21, 2000 (Issue: 1072)
Gatifloxacin and moxifloxacin are now available for once-daily treatment of patients with community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, or acute sinusitis.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Gatifloxacin and Moxifloxacin: Two New Fluoroquinolones
Article code: 1072a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.